8-K: SeaStar Medical Secures $4 Million Through Registered Direct Offering and Concurrent Private Placement

SeaStar Medical Holding Corporation announced a $4 million registered direct offering and concurrent private placement of common stock and warrants to fund general corporate purposes, including ongoing clinical trials and commercialization efforts.

Summary

• SeaStar Medical entered into a Securities Purchase Agreement on July 10, 2025, with certain institutional investors for a registered direct offering and a concurrent private placement.
• The registered direct offering includes the sale and issuance of 4,841,232 shares of common stock and pre-funded warrants to purchase up to 401,232 shares of common stock at an exercise price of $0.001 per share.
• The concurrent private placement involves the issuance and sale of warrants to purchase up to an aggregate of 5,242,464 shares of common stock at an exercise price of $0.638 per share.
• The combined offering price for each share of common stock and accompanying common warrant was $0.763, while the combined offering price for each pre-funded warrant and accompanying common warrant was $0.762.
• H.C. Wainwright & Co., LLC acted as the exclusive placement agent, receiving a cash fee equal to 7.0% of the aggregate gross proceeds, a management fee of 1.0% of gross proceeds, a non-accountable expense allowance of $25,000, reimbursement of up to $50,000 for legal and out-of-pocket expenses, and a closing fee of $15,950.
• The company also agreed to issue Placement Agent Warrants to H.C. Wainwright & Co., LLC or its designees, to purchase up to 366,972 shares of common stock at an exercise price of $0.9538 per share, exercisable upon issuance and expiring on July 10, 2030.
• The net proceeds from the offering, after deducting fees and expenses, are expected to be approximately $3.6 million, excluding any proceeds from the exercise of the common warrants and placement agent warrants.
• The company intends to use the net proceeds for general corporate purposes, including costs and expenses associated with being a public company.
• The offering is expected to close on July 11, 2025.

Sentiment

Score: 6

Explanation: The capital raise provides essential funding for SeaStar Medical's operations and clinical development, which is a positive for a company in its stage. However, the significant dilution from the issuance of new shares and warrants, coupled with the relatively low warrant exercise prices, indicates a capital raise under less optimal terms for existing shareholders, balancing the overall sentiment to neutral-positive.

Positives

• Secured approximately $3.6 million in net proceeds, providing capital for general corporate purposes, including working capital and capital expenditures.
• The capital raise supports ongoing operations and clinical trials, including the pivotal trial for SCD therapy in adult AKI patients.
• QUELIMMUNE (SCD-PED) received FDA approval in 2024 for life-threatening acute kidney injury (AKI) due to sepsis in critically ill pediatric patients.
• Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, potentially accelerating approval and improving reimbursement dynamics.

Negatives

• Significant dilution for existing shareholders due to the issuance of 4,841,232 new shares and warrants to purchase an additional 5,242,464 shares (Common Warrants) and 366,972 shares (Placement Agent Warrants).
• The exercise price of the Common Warrants ($0.638) is below the combined offering price of $0.763, indicating a discount.
• The company will incur costs and expenses associated with being a public company, which will be funded by the offering proceeds.
• The company has agreed to a 45-day lock-up period on certain equity issuances and a six-month prohibition on variable rate transactions, limiting immediate financing flexibility.

Risks

• Risk that SeaStar Medical may not be able to obtain regulatory approval of its SCD product candidates.
• Risk that SeaStar Medical may not be able to raise sufficient capital to fund its operations, including current or future clinical trials.
• Risk that SeaStar Medical and its current and future collaborators are unable to successfully develop and commercialize its products or services, or experience significant delays in doing so, including failure to achieve approval of its products by applicable federal and state regulators.
• Risk that SeaStar Medical may never achieve or sustain profitability.
• Risk that SeaStar Medical may not be able to secure additional financing on acceptable terms.
• Risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations.
• Risk of product liability or regulatory lawsuits or proceedings relating to SeaStar Medical's products and services.
• Risk that SeaStar Medical is unable to secure or protect its intellectual property.
• Market and other conditions may adversely affect the company's business and financial performance.

Future Outlook

SeaStar Medical intends to use the net proceeds from the offering for general corporate purposes, including additions to working capital and capital expenditures, and costs and expenses associated with being a public company. The company is currently conducting a pivotal trial of its Selective Cytopheretic Device (SCD) therapy in adult patients with Acute Kidney Injury (AKI) requiring continuous renal replacement therapy.

Management Comments

• SeaStar Medical intends to use the net proceeds of this offering for general corporate purposes, which may include additions to working capital and capital expenditures.

Industry Context

This capital raise by SeaStar Medical, a commercial-stage healthcare company specializing in treatments for critically ill patients with organ failure, is consistent with the financing needs of biotechnology and medical device companies, which often require significant capital for research, development, clinical trials, and commercialization efforts. The focus on Acute Kidney Injury (AKI) and sepsis, particularly with FDA-approved products and Breakthrough Device Designations, positions the company in a high-need, high-potential segment of the healthcare industry. The offering provides necessary funding to advance its pipeline and commercialization of QUELIMMUNE, aligning with typical growth strategies in the sector.

Stakeholder Impact

• Shareholders will experience immediate dilution from the issuance of new common stock and potential future dilution upon the exercise of warrants.
• The capital infusion provides financial stability, enabling the company to continue its research, development, and commercialization efforts, which could benefit long-term shareholder value if successful.
• Employees benefit from the continued funding of operations, supporting job security and potential growth opportunities.
• Patients and the broader healthcare community may benefit from the advancement and potential commercialization of SeaStar Medical's therapies for critical conditions like AKI and sepsis.

Next Steps

• Closing of the offering is expected on July 11, 2025.
• The company is required to file a registration statement for the resale of Common Warrant Shares and Placement Agent Warrant Shares within 30 calendar days after June 10, 2025.
• The company will use the net proceeds for general corporate purposes, including additions to working capital and capital expenditures.
• The company is currently conducting a pivotal trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy.
• The company will apply to list all of the newly issued Shares and Warrant Shares on Nasdaq and will use best efforts to maintain its listing.

Key Dates

Keywords

SeaStar Medical, ICU, Registered Direct Offering, Private Placement, Common Stock, Warrants, Pre-Funded Warrants, Capital Raise, SEC Filing, 8-K, Healthcare, Medical Devices, AKI, Acute Kidney Injury, Sepsis, QUELIMMUNE, SCD Therapy, Breakthrough Device Designation, Clinical Trials, Nasdaq